Mutual Advisors LLC Sells 1,005 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Mutual Advisors LLC lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 22,073 shares of the biopharmaceutical company’s stock after selling 1,005 shares during the period. Mutual Advisors LLC’s holdings in Gilead Sciences were worth $2,023,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of GILD. nVerses Capital LLC bought a new position in Gilead Sciences during the third quarter worth about $25,000. Valued Wealth Advisors LLC lifted its position in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 161 shares during the last quarter. Decker Retirement Planning Inc. acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $29,000. Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences during the second quarter worth approximately $33,000. Finally, Quarry LP acquired a new stake in Gilead Sciences during the second quarter worth approximately $43,000. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other news, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of the company’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the transaction, the chief financial officer now owns 138,919 shares in the company, valued at $12,886,126.44. This represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 456,234 shares of company stock worth $42,130,461 over the last quarter. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on GILD. Cantor Fitzgerald restated a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research report on Wednesday, December 11th. Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $74.00 to $96.00 in a research report on Monday, October 21st. JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Finally, UBS Group lifted their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Eleven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $97.96.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $93.07 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The stock has a market cap of $115.99 billion, a price-to-earnings ratio of 1,034.11, a P/E/G ratio of 1.31 and a beta of 0.18. The company’s fifty day moving average is $91.65 and its 200 day moving average is $84.68.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.29 earnings per share. Sell-side analysts forecast that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were issued a $0.77 dividend. The ex-dividend date was Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.31%. Gilead Sciences’s payout ratio is 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.